drugset
drugset / Trial / NCT03370289

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

NCT03370289 ↗

Phase 4 Completed 55 enrolled Takeda
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.

Timeline

Start
2018-01-12
Primary completion
2018-02-28
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BLB-750 Vaccine 7.5 ug Intramuscular
Subject BLB-750 Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.